{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Weiss E"],"funding":["European Union’s Seventh Framework Programme","European Federation of Phamaceutical Idustries and Associations","NIAID NIH HHS","NIH","Innovative Medicines Initiative Joint Undertaking"],"pagination":["1912-1918"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9431655"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["69(11)"],"pubmed_abstract":["<h4>Background</h4>Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.<h4>Methods</h4>Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method.<h4>Results</h4>The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free day"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials."],"pmcid":["PMC9431655"],"funding_grant_id":["FP7/2007–2013","115523","U19 AI135964"],"pubmed_authors":["Shorr AF","Prokocimer P","Thamlikitkul V","Rex JH","Papazian L","Eggimann P","Chastre J","Weiss E","Rello J","Torres A","Zahar JR","Ewig S","Alder J","Engelhardt M","Asehnoune K","Lipman J","Poulakou G","Timsit JF","Wunderink RG","Bonten MJM","Kollef M","Talbot GH","Luna C","Palmer LB","De Waele J","Bassetti M","Dimopoulos G","Pagani L","Martin-Loeches I"],"additional_accession":[]},"is_claimable":false,"name":"Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.","description":"<h4>Background</h4>Randomized clinical trials (RCTs) in hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively) are important for the evaluation of new antimicrobials. However, the heterogeneity in endpoints used in RCTs evaluating treatment of HABP/VABP may puzzle clinicians. The aim of this work was to reach a consensus on clinical endpoints to consider in future clinical trials evaluating antimicrobial treatment efficacy for HABP/VABP.<h4>Methods</h4>Twenty-six international experts from intensive care, infectious diseases, and the pharmaceutical industry were polled using the Delphi method.<h4>Results</h4>The panel recommended a hierarchical composite endpoint including, by priority order, (1) survival at day 28, (2) mechanical ventilation-free day","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Nov","modification":"2025-04-19T07:29:19.381Z","creation":"2025-04-19T07:29:19.381Z"},"accession":"S-EPMC9431655","cross_references":{"pubmed":["30722013"],"doi":["10.1093/cid/ciz093"]}}